M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta BioSpaceJohnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront.OncologyRead full story pharminent August 17, 2026 (Last updated: August 21, 2026) BioSpace Johnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. Oncology Read full story Post navigation Previous: Novo Nordisk and AWS form AI partnership to speed drug discoveryNext: AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline Related Stories M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026 M&A / Deals Sandoz targets industry patent void with $322m Henlius deal pharminent August 17, 2026 M&A / Deals PTC takes a chance on Sangamo’s Fabry disease gene therapy pharminent August 13, 2026
